Donepezil for Fatigue and Psychological Symptoms in Post–COVID-19 Condition DOI Creative Commons
Kensuke Nakamura,

Kazuhiro Kondo,

Naomi Oka

и другие.

JAMA Network Open, Год журнала: 2025, Номер 8(3), С. e250728 - e250728

Опубликована: Март 17, 2025

Importance Fatigue is the most commonly reported symptom of post–COVID-19 condition (also known as long COVID) and impairs various functions. One underlying mechanisms may be intracerebral inflammation due to decreases in acetylcholine levels. Objective To examine effects donepezil hydrochloride, an acetylcholinesterase inhibitor, on fatigue psychological symptoms. Design, Setting, Participants A multicenter, double-blind randomized clinical trial was performed Japan. Between December 14, 2022, March 31, 2024, adult patients within 52 weeks onset COVID-19 with a global binary score 4 or greater Chalder Scale were into placebo group. Exposure The intervention conducted during 3-week period, hydrochloride being administered at dosage 3 mg/d for first week then 5 2 weeks. Main Outcomes Measures primary outcome change absolute after initiation treatment. Other outcomes 8 weeks, such symptoms quality life, evaluated secondary outcomes. Results total 120 eligible enrolled 10 withdrew lost follow-up; therefore, 110 (55 each group) included efficacy analysis (64 [58%] female; mean [SD] age, 43 [12] years). No significant differences observed baseline characteristics between groups. baseline-adjusted estimating treatment effect donepezil, measured difference scores 0.34 (95% CI, −2.23 2.91), showing no ( P = .79). Scores Hospital Anxiety Depression Scale, Impact Event Scale–Revised, EuroQol 5-Dimension 5-Level Version, Patient Health Questionnaire, Daily Status similar. serious adverse events occurred either Conclusions Relevance In this treat condition, not confirmed general population. development effective therapeutics needed, more trials should future. Trial Registration Japan Registry Clinical Trials Identifier: jRCT 2031220510

Язык: Английский

Donepezil for Fatigue and Psychological Symptoms in Post–COVID-19 Condition DOI Creative Commons
Kensuke Nakamura,

Kazuhiro Kondo,

Naomi Oka

и другие.

JAMA Network Open, Год журнала: 2025, Номер 8(3), С. e250728 - e250728

Опубликована: Март 17, 2025

Importance Fatigue is the most commonly reported symptom of post–COVID-19 condition (also known as long COVID) and impairs various functions. One underlying mechanisms may be intracerebral inflammation due to decreases in acetylcholine levels. Objective To examine effects donepezil hydrochloride, an acetylcholinesterase inhibitor, on fatigue psychological symptoms. Design, Setting, Participants A multicenter, double-blind randomized clinical trial was performed Japan. Between December 14, 2022, March 31, 2024, adult patients within 52 weeks onset COVID-19 with a global binary score 4 or greater Chalder Scale were into placebo group. Exposure The intervention conducted during 3-week period, hydrochloride being administered at dosage 3 mg/d for first week then 5 2 weeks. Main Outcomes Measures primary outcome change absolute after initiation treatment. Other outcomes 8 weeks, such symptoms quality life, evaluated secondary outcomes. Results total 120 eligible enrolled 10 withdrew lost follow-up; therefore, 110 (55 each group) included efficacy analysis (64 [58%] female; mean [SD] age, 43 [12] years). No significant differences observed baseline characteristics between groups. baseline-adjusted estimating treatment effect donepezil, measured difference scores 0.34 (95% CI, −2.23 2.91), showing no ( P = .79). Scores Hospital Anxiety Depression Scale, Impact Event Scale–Revised, EuroQol 5-Dimension 5-Level Version, Patient Health Questionnaire, Daily Status similar. serious adverse events occurred either Conclusions Relevance In this treat condition, not confirmed general population. development effective therapeutics needed, more trials should future. Trial Registration Japan Registry Clinical Trials Identifier: jRCT 2031220510

Язык: Английский

Процитировано

0